Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Pfizer
GlaxoSmithKline
Information provided by (Responsible Party):
Maryellen Sun, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00749320
First received: September 5, 2008
Last updated: June 16, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)